Eads & Heald Wealth Management Has $2.88 Million Stock Holdings in Cencora, Inc. $COR

Eads & Heald Wealth Management lessened its position in Cencora, Inc. (NYSE:COR) by 5.9% in the second quarter, HoldingsChannel.com reports. The fund owned 9,605 shares of the company’s stock after selling 603 shares during the period. Cencora comprises about 1.4% of Eads & Heald Wealth Management’s portfolio, making the stock its 15th biggest holding. Eads & Heald Wealth Management’s holdings in Cencora were worth $2,880,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Voleon Capital Management LP bought a new stake in Cencora in the 1st quarter valued at about $3,111,000. Exchange Traded Concepts LLC grew its stake in shares of Cencora by 4.5% during the first quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock worth $307,000 after buying an additional 48 shares during the last quarter. Focus Partners Wealth lifted its stake in shares of Cencora by 25.8% in the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after acquiring an additional 1,171 shares during the last quarter. Fiduciary Alliance LLC bought a new position in shares of Cencora in the 2nd quarter valued at $262,000. Finally, Martin Capital Partners LLC boosted its stake in shares of Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after purchasing an additional 2,544 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the transaction, the chief executive officer directly owned 39,274 shares of the company’s stock, valued at $11,389,460. The trade was a 11.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,993 shares of company stock valued at $16,292,923 over the last quarter. Company insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on COR. Wells Fargo & Company increased their price objective on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a report on Saturday, September 27th. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Finally, Jefferies Financial Group lifted their price objective on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $311.25.

Cencora Stock Performance

Shares of COR opened at $302.54 on Monday. The stock’s fifty day moving average price is $294.68 and its two-hundred day moving average price is $290.41. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $315.23. The firm has a market cap of $58.66 billion, a PE ratio of 31.13, a PEG ratio of 1.41 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $3.34 earnings per share. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were given a $0.55 dividend. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is 22.63%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.